Health & Research Goals
SLU-PP-332
SLU-PP-332 is a small molecule ERR (estrogen-related receptor) pan-agonist developed by researchers at Washington University in St…
Primary Description
SLU-PP-332 is a small molecule ERR (estrogen-related receptor) pan-agonist developed by researchers at Washington University in St. Louis. It activates all three estrogen-related receptor subtypes — ERRalpha, ERRbeta, and ERRgamma — which are master regulators of mitochondrial biogenesis, oxidative metabolism, and energy expenditure. SLU-PP-332 is sometimes referred to as an 'exercise mimetic' because it activates many of the same molecular pathways triggered by aerobic exercise — without the physical exertion. In rodent studies it produced significant fat loss, improved exercise tolerance, protection against diet-induced obesity, and markers of enhanced mitochondrial function. While technically not a peptide, SLU-PP-332 is distributed by peptide research vendors and has attracted significant interest in the longevity and metabolic optimization community. Human clinical data is not yet available as of 2026.
Key Benefits
- ERRα/γ agonist — activates the "exercise gene program" without movement
- Mitochondrial biogenesis and fat oxidation (preclinical: 50% increase in aerobic endurance)
- Cardioprotective signaling via cardiac ERRα activation
Store at -20°C to -80°C for long-term storage. Short-term (1 month) stable at 4°C. Dissolve in DMSO for research applications. Protect from light and moisture. Research-grade compound — human clinical formulations not established.
Demonstrated Effects
- Activates mitochondrial biogenesis via ERRalpha, ERRbeta, ERRgamma co-activation
- Promotes fat oxidation and reduces diet-induced obesity in rodent models
- Enhances aerobic exercise capacity — treadmill endurance increased 70% in mice
- Activates PGC-1alpha pathway (the master metabolic switch for mitochondrial function)
- Mimics molecular effects of aerobic exercise at the transcriptional level
- Protective against metabolic syndrome and obesity-related comorbidities in preclinical models
- May preserve muscle mass and function (sarcopenia prevention potential)
- Potentially synergistic with actual exercise for amplified metabolic benefits
- Interest for conditions where exercise is limited (mobility impairment, cardiac rehabilitation)
Proposed Mechanisms of Action
1. ERR Pan-Agonism (ERRalpha, ERRbeta, ERRgamma)
SLU-PP-332 simultaneously activates all three estrogen-related receptor subtypes. ERRs are nuclear receptors that regulate transcription of hundreds of genes governing mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and energy homeostasis.
2. PGC-1alpha Pathway Activation
ERR agonism converges on PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) — the master regulator of mitochondrial biogenesis and oxidative metabolism. This is the same pathway activated by endurance exercise.
3. Mitochondrial Biogenesis
Upregulation of ERR target genes drives formation of new mitochondria in skeletal muscle and other metabolically active tissues, increasing oxidative capacity and energy expenditure.
4. Enhanced Fatty Acid Oxidation
ERR-driven gene expression programs shift cellular metabolism toward increased fat oxidation, reducing lipid accumulation and promoting lipolysis in adipose and muscle tissue.
Research Evidence & Clinical Data
Investigated Applications
Exercise Mimicry and Metabolic Enhancement
Anecdotal: EmergingSLU-PP-332's most compelling potential is as an exercise mimetic — activating the same ERR-driven transcriptional programs as aerobic exercise. In mice, 4 weeks of SLU-PP-332 produced a 70% increase in treadmill endurance, significant fat loss, and improved metabolic markers. Human data is absent but community interest is high.
Preclinical basis: Perry et al. (2023, Nature Metabolism): SLU-PP-332 activated ERR target genes, increased mitochondrial content, reduced obesity markers, and improved exercise performance in mice.
Fat Loss and Anti-Obesity
Anecdotal: EmergingDiet-induced obese mice treated with SLU-PP-332 showed significant reductions in body weight and fat mass without caloric restriction. The mechanism involves upregulation of fat oxidation genes in skeletal muscle and adipose tissue.
Preclinical basis: In diet-induced obesity mouse models, SLU-PP-332 treatment reduced fat mass and improved glucose tolerance via ERR-dependent transcriptional reprogramming of metabolic tissues.
Sarcopenia and Muscle Preservation
Anecdotal: EmergingERR agonism promotes mitochondrial health in skeletal muscle, which is directly related to muscle quality and resistance to age-related sarcopenia. Preclinical data suggests SLU-PP-332 may preserve muscle function and metabolic integrity in aging.
Preclinical basis: ERRalpha and ERRgamma are highly expressed in oxidative skeletal muscle fibers and their activation promotes mitochondrial biogenesis and metabolic capacity critical for muscle health.
Scientific References
- 1.A Synthetic ERR Agonist Alleviates Metabolic SyndromeJ Pharmacol Exp Ther2024
- 2.
- 3.
Safety Profile
Common Side Effects
- Unknown in humans — no clinical trial data available as of 2026
Contraindications
- No established human contraindications — insufficient data
- Pregnancy and breastfeeding (avoid — no safety data)
- Children (avoid)
- Hormone-sensitive cancers (ERR pathway relevance unknown in this context)
Legal & Regulatory Status
Not FDA-approved for any indication. Research compound only. Not available as a pharmaceutical. Distributed through research chemical and peptide vendors. Not a controlled substance. Human use is experimental with no established safety profile.
No aprobado por la FDA para ninguna indicación. Compuesto de investigación solamente. No disponible como fármaco. Distribuido a través de proveedores de químicos de investigación y péptidos. No es una sustancia controlada. El uso en humanos es experimental sin perfil de seguridad establecido.
Research Protocols
Dosing Protocols
Routes of Administration
oral (in research)
subcutaneous (in research)
Reconstitution Guide
Pharmacokinetics
| Half-Life | Unknown in humans. Animal pharmacokinetics not fully published. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Comprehensive metabolic monitoring
- Liver function every 4 weeks
- Cardiac monitoring
- Body composition tracking
- Hormone panel monitoring
Critical Warning Signs
- Any unexpected cardiovascular symptoms
- Liver enzyme elevation
- Hormonal disruption symptoms
- Any adverse reaction — discontinue immediately
Featured in Stacking Protocols
Community-researched combinations involving this compound